Dr Reddy Stock
Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts
Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.
 "Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts")
New launches, regulatory go-ahead key triggers for Dr Reddy's
Sales in the US, its biggest market, accounting for 37 per cent of revenues, were up 8 per cent year-on-year (YoY) and 12 per cent sequentially, led by five new launches
 "New launches, regulatory go-ahead key triggers for Dr Reddy's")
Technical calls by Religare Broking: Buy Dr Reddy's Lab, Ramco Cements
Weekly Technical Recommendations by Religare Broking Ltd.
 "Technical calls by Religare Broking: Buy Dr Reddy's Lab, Ramco Cements")
Dr Reddy's Labs shines among pharma stocks, wins investor confidence
The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year
 "Dr Reddy's Labs shines among pharma stocks, wins investor confidence")
PSAI segment decline pulls down Dr Reddy's Q1 show
Earnings were driven by one-off gains
 "PSAI segment decline pulls down Dr Reddy's Q1 show")
Dr Reddy's stock: Product pipeline should boost revenue growth in FY19
Analysts at Nomura believe there is a strong probability that the company will get approval in the near term for Suboxone & expect initially lower competitive intensity
 "Dr Reddy's stock: Product pipeline should boost revenue growth in FY19")
